At a Glance
| Parameter | Detail |
|---|---|
| Mechanism | NMDA antagonism → BDNF release → rapid synaptogenesis |
| Standard depression course | 6 infusions over 2–3 weeks |
| Dose range | 0.5 mg/kg IV over 40 min (depression); 0.1–0.5 mg/kg for pain |
| Onset of effect | 2–4 hours post-infusion |
| Response rate (TRD) | 50–70% after full course |
| Duration of remission | 2–8 weeks without maintenance; longer with boosters |
| Contraindications | Uncontrolled hypertension, active psychosis, schizophrenia, severe substance use disorder |
| Evidence level | Level I for TRD; Level II for chronic pain syndromes |
Ketamine entered clinical consciousness as an anesthetic agent in 1970, yet its most compelling modern application may be neuropsychiatric. For patients who have failed two or more antidepressants — the textbook definition of treatment-resistant depression (TRD) — IV ketamine offers something no SSRI or SNRI can: measurable relief within hours, not weeks. A growing body of randomized controlled trials, multiple meta-analyses, and now FDA approval of its intranasal cousin esketamine (Spravato) have moved ketamine from anesthetic curiosity to mainstream psychiatric intervention.
In integrative medicine practice, the patient population that presents for ketamine therapy is rarely straightforward. Depression overlapping with chronic Lyme sequelae, post-COVID neuroinflammation, fibromyalgia, or complex PTSD is common. This overlap is clinically important because ketamine’s mechanism — NMDA receptor antagonism followed by BDNF-mediated synaptogenesis — addresses the neuroinflammatory and neuroplasticity deficits shared across these conditions.
Mechanism: Beyond NMDA Blockade
Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, a glutamate-gated ion channel critical to synaptic plasticity. Classical antidepressants modulate monoamines (serotonin, norepinephrine, dopamine) on a timescale of weeks. Ketamine bypasses this entirely.
The Glutamate Burst Hypothesis
When NMDA receptors at inhibitory interneurons are blocked, glutamate surges onto AMPA receptors. This activates mTOR signaling and releases BDNF (brain-derived neurotrophic factor), which drives rapid dendritic spine growth. In depressed brains — where prefrontal-limbic synaptic density is measurably reduced — this surge of synaptogenesis restores connectivity within hours. Functional imaging studies show normalization of default mode network hyperactivity and restored prefrontal-amygdala coupling after a single infusion.
Anti-Inflammatory Effects
Ketamine also suppresses microglial activation and reduces pro-inflammatory cytokines (IL-6, TNF-α) in the CNS. This is mechanistically relevant in patients with treatment-resistant depression driven by neuroinflammation — increasingly recognized as a major driver in Lyme, long COVID, and autoimmune-related mood disorders. A 2023 study in Neuropsychopharmacology demonstrated that pre-treatment CRP and IL-6 levels predicted ketamine response in TRD: higher baseline inflammation paradoxically correlated with better antidepressant outcomes, suggesting anti-neuroinflammatory action as an independent mechanism.
Opioid System Involvement
A 2023 Stanford study (Williams et al., Nature Medicine) demonstrated that blocking opioid receptors with naltrexone abolished ketamine’s antidepressant — but not dissociative — effect. This finding suggests the mu-opioid system mediates part of ketamine’s mood benefit, complicating the purely glutamatergic narrative and raising questions about patient selection in those with prior opioid use.
Who Is a Candidate
Treatment-Resistant Depression (TRD)
The primary indication. Standard criteria require failure of ≥2 antidepressant trials at adequate dose and duration. Meta-analyses of randomized placebo-controlled trials show response rates of 50–70% and remission rates of 25–40% after a 6-infusion course. Importantly, prior antidepressant failure does not predict ketamine non-response — the mechanism is orthogonal.
Bipolar Depression
Ketamine shows efficacy in bipolar II depression where antidepressant monotherapy risks cycle acceleration. The evidence base is smaller but growing; a 2022 RCT in JAMA Psychiatry found similar response rates to unipolar TRD. Close monitoring for hypomanic switching is required; combining ketamine with a mood stabilizer is standard.
Suicidality and Acute Crisis
Ketamine’s most clinically urgent application is acute suicidality. A single infusion has been shown to reduce suicidal ideation within hours — a therapeutic window no oral agent can match. Emergency settings are increasingly deploying subanesthetic ketamine for acute suicidal crises pending psychiatric disposition.
Chronic Pain Conditions
Ketamine disrupts central sensitization — the pathological wind-up of pain circuits common to fibromyalgia, complex regional pain syndrome (CRPS), neuropathic pain, and post-herpetic neuralgia. In chronic pain protocols, lower doses (0.1–0.35 mg/kg/hour) over longer infusion windows (2–4 hours per session) are used. Response in CRPS is particularly well-documented; a 2021 Cochrane review found moderate-quality evidence for meaningful pain reduction lasting weeks to months.
Post-COVID and Neuroinflammatory Overlap
In patients with long COVID brain fog, post-Lyme mood dysregulation, or CIRS-related neuropsychiatric symptoms, ketamine’s anti-inflammatory and synaptogenic actions offer a theoretically sound approach. Clinical experience in this population is accumulating, though controlled trial data remain limited.
Protocol: What a Course Looks Like
Standard TRD Induction
The validated induction protocol consists of 6 infusions over 2–3 weeks, typically arranged as three infusions per week on alternating days (e.g., Monday/Wednesday/Friday, repeat). This schedule is derived from the pivotal RCTs (Murrough et al., 2013; Mathew et al., 2010) and is now considered the minimum for durability of response.
| Session | Dose | Duration | Notes |
|---|---|---|---|
| 1–2 | 0.5 mg/kg | 40 min | Establish tolerance, assess dissociation |
| 3–4 | 0.5 mg/kg | 40 min | Dose adjustment if needed |
| 5–6 | 0.5–0.75 mg/kg | 40 min | Optimization phase |
The 0.5 mg/kg over 40-minute infusion is the reference dose established in academic psychiatry. Some clinicians titrate up to 0.75 mg/kg in partial responders; higher doses increase dissociative side effects without proportional benefit for most patients.
Pre-Infusion Assessment
Before the first session, patients should undergo:
- Cardiovascular evaluation (ketamine raises blood pressure by 15–25 mmHg; baseline hypertension must be controlled)
- Psychiatric evaluation to exclude active psychosis or schizophrenia spectrum disorder
- Substance use history (active stimulant or alcohol dependence is a relative contraindication)
- Current medication review — MAOIs are absolutely contraindicated; benzodiazepines may blunt response
During the Infusion
Patients remain in a monitored recliner. Vital signs (BP, HR, SpO2) are checked every 5–10 minutes. Dissociative symptoms are expected and normal at therapeutic doses — patients typically describe floating, altered spatial perception, and time distortion. This peaks at 20–30 minutes and resolves within 30–60 minutes post-infusion. Eye shades and headphones with curated music can enhance therapeutic set-and-setting.
A companion or driver is required. Patients should plan for 2–3 hours at the clinic and should not make major decisions on the day of infusion.
Maintenance and Booster Dosing
Without maintenance, antidepressant effects typically last 2–8 weeks. Two strategies extend remission:
- Booster infusions: Single monthly or bimonthly infusions keyed to early symptom recurrence. Most patients learn their personal warning signs within the first course.
- Intranasal esketamine (Spravato): FDA-approved for TRD and MDD with suicidal ideation, esketamine is the S-enantiomer of ketamine administered biweekly after remission. It allows in-office dosing without IV access, though at higher pharmaceutical cost.
Combining maintenance ketamine with psychotherapy (ketamine-assisted psychotherapy, KAP) is supported by emerging evidence; the neuroplastic window post-infusion appears to enhance therapeutic alliance and cognitive restructuring.
Side Effects and Safety
Dissociation
Expected and dose-dependent. At 0.5 mg/kg, most patients experience mild perceptual changes; severe ego dissolution is unusual at standard doses. The dissociative experience is manageable with preparation and integration support.
Cardiovascular
Transient hypertension and tachycardia are universal. Blood pressure increases of 15–25% are typical. Patients with baseline hypertension or cardiovascular disease require careful pre-treatment optimization and intra-session monitoring. For most healthy adults, this transient elevation is clinically insignificant.
Nausea
Occurs in 15–30% of patients, peaking during infusion. Pre-treatment with ondansetron 4 mg IV substantially reduces this.
Cognitive Effects
Short-term working memory impairment persists for 1–2 hours post-infusion. No long-term cognitive toxicity has been demonstrated in standard treatment courses. High-frequency recreational use (not clinical protocols) has been associated with ulcerative cystitis and persistent cognitive impairment — an important distinction when counseling patients.
Dependency Risk
Clinical ketamine courses carry a low dependency risk when protocols are adhered to. The dissociative experience is generally not reinforcing at subanesthetic doses. However, patients with a history of ketamine or dissociative drug misuse require individual risk assessment.
Integrative Considerations
In a functional medicine context, ketamine works best as part of a broader neuroplasticity program:
- Sleep optimization: The synaptogenic window post-infusion extends through the first 72 hours. Deep sleep is essential for BDNF-mediated consolidation; sleep architecture should be addressed before beginning a course.
- Nutritional support: Magnesium glycinate (400–500 mg at bedtime) modulates NMDA receptors and may prolong ketamine’s effects. Low magnesium status correlates with NMDA receptor hypersensitivity and poorer antidepressant outcomes.
- Psychotherapy integration: Structured therapy sessions scheduled within 24–72 hours of each infusion capitalize on the neuroplastic window. Acceptance and commitment therapy (ACT) and EMDR show particular synergy.
- Inflammation control: Given the anti-inflammatory mechanism, concurrent treatment of underlying neuroinflammation (gut dysbiosis, mold/CIRS burden, reactivated infections) may amplify and prolong response.
Related Articles
- Transcranial Magnetic Stimulation for Anxiety: Evidence and Protocol
- TMS for Depression: What the Evidence Actually Shows
- Photobiomodulation for Brain Fog and Neuroinflammation
- Vagus Nerve Stimulation for Chronic Inflammation
- PEMF Therapy: Frequency Guide and Indications
References
- Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250–256. PMID: 23434389
- Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an NMDA antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864. PMID: 16894061
- Williams NR, Heifets BD, Blasey C, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175(12):1205–1215. PMID: 30153752
- Short B, Fong J, Galvez V, et al. Side effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5(1):65–78. PMID: 29102430
- Corriger A, Pickering G. Ketamine and depression: a narrative review. Drug Des Devel Ther. 2019;13:3051–3067. PMID: 31695320
- Sigtermans MJ, van Hilten JJ, Bauer MC, et al. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain. 2009;145(3):304–311. PMID: 19604642
- Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68–72. PMID: 23042884